Zimmer Biomet Holdings, Inc. (ZBH)
| Market Cap | 17.54B |
| Revenue (ttm) | 8.01B |
| Net Income (ttm) | 805.30M |
| Shares Out | 198.18M |
| EPS (ttm) | 4.03 |
| PE Ratio | 21.94 |
| Forward PE | 10.52 |
| Dividend | $0.96 (1.08%) |
| Ex-Dividend Date | Sep 30, 2025 |
| Volume | 2,018,231 |
| Open | 89.12 |
| Previous Close | 88.73 |
| Day's Range | 87.44 - 89.75 |
| 52-Week Range | 85.33 - 114.72 |
| Beta | 0.61 |
| Analysts | Buy |
| Price Target | 108.56 (+22.67%) |
| Earnings Date | Nov 5, 2025 |
About ZBH
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open hear... [Read more]
Financial Performance
In 2024, Zimmer Biomet Holdings's revenue was $7.68 billion, an increase of 3.85% compared to the previous year's $7.39 billion. Earnings were $903.80 million, a decrease of -11.74%.
Financial StatementsAnalyst Summary
According to 19 analysts, the average rating for ZBH stock is "Buy." The 12-month stock price target is $108.56, which is an increase of 22.67% from the latest price.
News
Zimmer Biomet to Present at the Annual Jefferies Global Healthcare Conference in London
WARSAW, Ind., Nov. 7, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that members of the Zimmer Biomet management team will ...
Time To Buy Zimmer Biomet Stock?
Zimmer Biomet (ZBH) stock ought to be on your radar. Here's why – it is presently trading within the support range ($83.17 – $91.93), levels from which it has rebounded significantly in the past.
Zimmer Biomet Holdings, Inc. (ZBH) Q3 2025 Earnings Call Transcript
Zimmer Biomet Holdings, Inc. ( ZBH) Q3 2025 Earnings Call November 5, 2025 8:30 AM EST Company Participants David DeMartino - Senior Vice President of Investor Relations Ivan Tornos - President, CEO ...
Zimmer Biomet Stock Falls As Weakness In Latin America And Certain EU Markets Impact Organic Growth Forecast
Zimmer Biomet Holdings, Inc. (NYSE:ZBH) reported third-quarter adjusted earnings of $1.90 per share, up 9.2% year over year, beating the Street estimates of $1.87.
This Healthcare Stock Is the Worst Performer in the S&P 500 Today. Here's Why.
Zimmer Biomet, the maker of knee and hip replacements, missed on quarterly sales estimates and lowered the top end of its outlook for full-year organic revenue growth.
Zimmer cuts 2025 organic sales growth forecast on weakness in international markets
Zimmer Biomet Holdings cut its 2025 organic revenue growth forecast following weakness in Latin America and emerging markets in Europe that offset the company's strong performance in the U.S., sending...
Zimmer Biomet Announces Third Quarter 2025 Financial Results
Third quarter net sales of $2.001 billion increased 9.7% on a reported basis, 8.6% on a constant currency1 basis and 5.0% on an organic constant currency1 basis Third quarter diluted earnings per shar...
Zimmer Biomet Announces FDA Breakthrough Designation for World's First Iodine-Treated Total Hip Replacement System
Prioritized Regulatory Review Process in the U.S. Follows Japan PMDA Approval in September WARSAW, Ind., Oct. 28, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medica...
Zimmer Biomet Highlights Robotics & Musculoskeletal Product Innovations at 2025 AAHKS Annual Meeting
Company to Spotlight Comprehensive Hip & Knee Portfolios and Latest Advancements in Robotics, Including the mBôs™ System Following Recent Acquisition of Monogram Technologies WARSAW, Ind., Oct. 21, 20...
Zimmer Biomet Q3 Earnings To Highlight Innovation And Growth - Why I Think It's A Buy
Zimmer Biomet Holdings is rated a BUY, driven by innovation momentum and undervalued valuation despite recent stock underperformance. ZBH's 'Magnificent 7' products, strategic acquisitions like Monogr...
Zimmer Biomet Launches Two New Foot and Ankle Solutions for Complex Trauma Cases
Gorilla® Pilon Fusion Plating System Introduced for Complex Ankle Fusions Phantom® TTC Trauma Nail Enhances Treatment Options for Complex Hindfoot Injuries WARSAW, Ind., Oct. 8, 2025 /PRNewswire/ -- Z...
Zimmer Biomet Completes Acquisition of Monogram Technologies
Transaction creates the broadest, most flexible portfolio of orthopedic robotics and navigation technologies, including pathway towards the first fully autonomous robotic technology for orthopedic pr...
I2Pure Celebrates Zimmer Biomet's Historic Approval of Iodine-Treated Implant System & Confirms AAHKS Attendance
ASHBURN, Va.--(BUSINESS WIRE)--I2Pure, a leader in molecular iodine technology, today celebrates Zimmer Biomet's recent achievement in receiving Japan's Pharmaceutical and Medical Devices Agency (PMDA...
Zimmer Biomet Announces Webcast and Conference Call of Third Quarter 2025 Financial Results
WARSAW, Ind. , Oct. 3, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced its third quarter earnings conference call will be webcast on Wednesday, November 5, 2025 a...
Zimmer Biomet Announces Japan PMDA Approval of World's First Iodine-Treated Total Hip Replacement System
iTaperloc® Complete and iG7™ Hip System with Iodine Technology inhibits bacterial adhesion and prevents biofilm formation on the implant surface to help address the issue of Periprosthetic Joint Infec...
Zimmer Biomet Holdings, Inc. (ZBH) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 8:30 AM EDT Company Participants Ivan Tornos - President, CEO & Chairman of the Board...
Zimmer Biomet to Showcase Foot and Ankle Portfolio at the American Orthopedic Foot and Ankle Society Annual Conference
WARSAW, Ind., Sept. 4, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced its participation in the American Orthopedic Foot and ...
Zimmer Biomet Announces New Chief Medical Advisors to Help Improve Standard of Musculoskeletal Care
Dr. Jonathan M. Vigdorchik Named Chief Medical Technology Advisor, Adult Reconstruction and Hip Implants Dr. Anand M.
Zimmer Biomet Announces Quarterly Dividend for Third Quarter of 2025
WARSAW, Ind. , Aug. 27, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that its Board of Directors has approved the payment ...
Zimmer Biomet to Present at the Annual Morgan Stanley Healthcare Conference
WARSAW, Ind. , Aug. 25, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced that members of the Zimmer Biomet management team will be presenting at the Annual Morgan ...
4 Stocks to Buy From a Top-Performing Fund Manager
Bill Nygren's Oakmark Fund recently took new positions in these undervalued stocks.
Zimmer Biomet Holdings, Inc. (ZBH) Q2 2025 Earnings Call Transcript
Zimmer Biomet Holdings, Inc. (ZBH) Q2 2025 Earnings Call Transcript
Zimmer Biomet's $2.08 Billion Q2 Sales Ignite Orthopedic Surge, Boosts Guidance Outlook
Zimmer Biomet Holdings, Inc. ZBH reported second-quarter adjusted earnings of $2.07 per share, up 3% year over year, beating the Street estimates of $1.99.
Zimmer Biomet raises annual profit forecast on strong demand for medical devices
Zimmer Biomet Holdings raised its full-year adjusted profit forecast and beat second-quarter earnings expectations on Thursday, bolstered by accelerating demand for its hip and knee implants.
Zimmer Biomet Q2 Preview: Combining Monogram Autonomous Robotics With ROSA
I reiterate my Buy rating on Zimmer Biomet Holdings, Inc., setting a fair value of $133 per ZBH share due to strong business acceleration opportunities. The Monogram Technologies acquisition could sig...